Pacira Financial Statements From 2010 to 2025

PCRX Stock  USD 23.67  0.36  1.54%   
Pacira BioSciences, financial statements provide useful quarterly and yearly information to potential Pacira BioSciences, investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pacira BioSciences, financial statements helps investors assess Pacira BioSciences,'s valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pacira BioSciences,'s valuation are summarized below:
Gross Profit
449 M
Profit Margin
(0.14)
Market Capitalization
1.1 B
Enterprise Value Revenue
1.7285
Revenue
701 M
We have found one hundred twenty available trending fundamental ratios for Pacira BioSciences,, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Pacira BioSciences, recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.7 B in 2025. Enterprise Value is likely to rise to about 1.8 B in 2025

Pacira BioSciences, Total Revenue

736.01 Million

Check Pacira BioSciences, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira BioSciences,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 82.7 M, Interest Expense of 15.8 M or Selling General Administrative of 67.3 M, as well as many indicators such as Price To Sales Ratio of 1.18, Dividend Yield of 0.0014 or PTB Ratio of 1.06. Pacira financial statements analysis is a perfect complement when working with Pacira BioSciences, Valuation or Volatility modules.
  
Check out the analysis of Pacira BioSciences, Correlation against competitors.
For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.

Pacira BioSciences, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.6 B1.6 B843.3 M
Slightly volatile
Other Current Liabilities296 M281.9 M73.2 M
Slightly volatile
Total Current Liabilities325.4 M309.9 M150.1 M
Slightly volatile
Total Stockholder Equity817.3 M778.3 M394.9 M
Slightly volatile
Other Liabilities24.9 M43.5 M24.7 M
Slightly volatile
Property Plant And Equipment Net127.2 M216.4 M128.1 M
Slightly volatile
Current Deferred Revenue41.1 M39.1 M24.6 M
Slightly volatile
Accounts Payable11 M19.1 M10.5 M
Slightly volatile
Cash290.6 M276.8 M140.1 M
Slightly volatile
Non Current Assets Total414.1 M808.4 M421.7 M
Slightly volatile
Non Currrent Assets Other17.8 M35.6 M18.1 M
Slightly volatile
Other Assets1.091.1538.4 M
Slightly volatile
Cash And Short Term Investments241.7 M276.8 M246.5 M
Slightly volatile
Net Receivables119 M113.3 M50.3 M
Slightly volatile
Common Stock Total Equity32.8 K51.8 K36.9 K
Slightly volatile
Common Stock Shares Outstanding36.8 M46.2 M36.7 M
Slightly volatile
Short Term Investments143.3 M207.8 M147.2 M
Slightly volatile
Liabilities And Stockholders Equity1.6 B1.6 B843.3 M
Slightly volatile
Non Current Liabilities Total288 M481.1 M286.8 M
Slightly volatile
Inventory131.5 M125.3 M57.6 M
Slightly volatile
Other Current Assets241.3 M229.8 M38.8 M
Slightly volatile
Other Stockholder Equity628.2 M984.3 M634.5 M
Slightly volatile
Total Liabilities423.3 M775.2 M424 M
Slightly volatile
Property Plant And Equipment Gross366.8 M349.3 M159.9 M
Slightly volatile
Total Current Assets782.4 M745.1 M394.4 M
Slightly volatile
Short Term Debt8.4 M8.9 M66.8 M
Pretty Stable
Intangible Assets447.3 M426 M184.5 M
Slightly volatile
Common Stock36 K47 K36.9 K
Slightly volatile
Property Plant Equipment307.2 M292.5 M138.3 M
Slightly volatile
Short and Long Term Debt Total361.2 M490 M330.4 M
Slightly volatile
Long Term Debt Total240.7 M360 M206.7 M
Slightly volatile
Capital Surpluse685.2 M1.1 B647 M
Slightly volatile
Non Current Liabilities Other36.4 M37.1 M28.4 M
Slightly volatile
Short and Long Term Debt108 M201.8 M77.6 M
Slightly volatile
Net Invested Capital1.1 B1.4 B824.9 M
Slightly volatile
Net Working Capital411.8 M435.2 M359.4 M
Slightly volatile
Capital Stock48.9 K47 K43 K
Slightly volatile
Capital Lease Obligations52.7 M53.5 M53.8 M
Slightly volatile

Pacira BioSciences, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization82.7 M78.8 M29 M
Slightly volatile
Interest Expense15.8 M13.4 M15.7 M
Slightly volatile
Selling General Administrative67.3 M122.1 M65.7 M
Slightly volatile
Total Revenue736 M701 M354 M
Slightly volatile
Other Operating Expenses813.1 M774.3 M353.6 M
Slightly volatile
Research Development49.2 M81.6 M47.8 M
Slightly volatile
Cost Of Revenue97 M170.4 M98.2 M
Slightly volatile
Total Operating Expenses813.1 M774.3 M272.2 M
Slightly volatile
Non Recurring2.4 M2.7 MM
Slightly volatile
Selling And Marketing Expenses113 M172 M94.3 M
Slightly volatile
Interest Income20.7 M19.7 M7.7 M
Slightly volatile
Reconciled Depreciation46.4 M78.8 M30.1 M
Slightly volatile

Pacira BioSciences, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation28.2 M51.2 M28.9 M
Slightly volatile
Begin Period Cash Flow94.5 M153.3 M95.9 M
Slightly volatile
Depreciation82.7 M78.8 M29.8 M
Slightly volatile
Capital Expenditures21.1 M10.6 M21 M
Slightly volatile
End Period Cash Flow290.6 M276.8 M124.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.181.24296.9319
Slightly volatile
Dividend Yield0.00140.00120.0018
Slightly volatile
PTB Ratio1.061.11947.8424
Slightly volatile
Days Sales Outstanding37.9958.998548.7527
Very volatile
Book Value Per Share17.6716.83110.1286
Slightly volatile
Stock Based Compensation To Revenue0.07130.0730.0969
Slightly volatile
Capex To Depreciation0.130.1351.4636
Slightly volatile
PB Ratio1.061.11947.8424
Slightly volatile
Inventory Turnover1.932.043.2727
Slightly volatile
Days Of Inventory On Hand119186162
Slightly volatile
Payables Turnover7.2310.599.9157
Pretty Stable
Sales General And Administrative To Revenue0.320.17420.3557
Slightly volatile
Research And Ddevelopement To Revenue0.110.11640.3413
Slightly volatile
Capex To Revenue0.01440.01520.1376
Slightly volatile
Cash Per Share8.795.98498.173
Very volatile
Days Payables Outstanding33.935.6851.6058
Slightly volatile
Intangibles To Total Assets0.150.27420.1846
Slightly volatile
Current Ratio2.552.40433.372
Pretty Stable
Receivables Turnover8.96.18667.7474
Very volatile
Shareholders Equity Per Share17.6716.83110.1286
Slightly volatile
Capex Per Share0.220.231.2048
Slightly volatile
Revenue Per Share8.0115.15779.4468
Pretty Stable
Interest Debt Per Share6.3810.88638.3604
Slightly volatile
Debt To Assets0.30.31540.3752
Pretty Stable
Graham Number13.7517.6516.4959
Slightly volatile
Operating Cycle56.0558.9985192
Very volatile
Price Book Value Ratio1.061.11947.8424
Slightly volatile
Days Of Payables Outstanding33.935.6851.6058
Slightly volatile
Company Equity Multiplier1.631.99592.4771
Slightly volatile
Quick Ratio2.212.02.907
Pretty Stable
Net Income Per E B T1.171.57771.4086
Pretty Stable
Cash Ratio1.220.8931.128
Pretty Stable
Days Of Inventory Outstanding119186162
Slightly volatile
Days Of Sales Outstanding37.9958.998548.7527
Very volatile
Price To Book Ratio1.061.11947.8424
Slightly volatile
Fixed Asset Turnover1.693.23932.2572
Slightly volatile
Debt Ratio0.30.31540.3752
Pretty Stable
Price Sales Ratio1.181.24296.9319
Slightly volatile
Asset Turnover0.340.45120.4298
Very volatile
Price Fair Value1.061.11947.8424
Slightly volatile

Pacira BioSciences, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.6 B1.5 B
Slightly volatile

Pacira Fundamental Market Drivers

Forward Price Earnings8.4459
Cash And Short Term Investments276.8 M

Pacira Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
1st of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Pacira BioSciences, Financial Statements

Pacira BioSciences, investors use historical fundamental indicators, such as Pacira BioSciences,'s revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pacira BioSciences,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue39.1 M41.1 M
Total Revenue701 M736 M
Cost Of Revenue170.4 M97 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 0.17  0.32 
Research And Ddevelopement To Revenue 0.12  0.11 
Capex To Revenue 0.02  0.01 
Revenue Per Share 15.16  8.01 
Ebit Per Revenue(0.10)(0.11)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.